Catalyst Biosciences

Catalyst Biosciences was a South San Francisco-based biopharmaceutical company focused on developing protein therapeutics for rare bleeding disorders including hemophilia. In 2023, GC Biopharma acquired Catalyst's rare hematology pipeline assets while Catalyst completed a reverse merger with GNI Group's Beijing Continent Pharmaceuticals, pivoting to fibrosis treatments.